SABCS 2022 | Long-term survival of the Phase II GeparOLA study
Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, shares the long-term outcome data of the Phase II GeparOLA (NCT02789332) investigating neoadjuvant paclitaxel plus olaparib in comparison to paclitaxel plus carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency. The GeparOLA study was designed to evaluate the efficacy and safety of the combination of paclitaxel plus olaparib as part of neoadjuvant chemotherapy in patients with HER2-negative, either HR-positive or HR-negative and homologous recombination deficiency (HRD) defined as having a BRCA mutation and/or a high HRD score. Primary analysis showed a pathologic complete response rate (pCR) rate of 55.1% with paclitaxel plus olaparib and 48.6% with paclitaxel plus carboplatinum, suggesting olaparib can be used instead of carboplatin. The long-term survival results demonstrated in the long-run carboplatinum remains better than olaparib, however, there is no difference observed in patients with BRCA mutations. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah, the GeparOLA study we present here is the long term data and we have already published the pathological complete response data in 2020 in Annals of Oncology, which demonstrated that exchanging carboplatin with olaparib in patients who have HRD, so defined as either BRCA mutation or having a HRD-high tumor by the MyChoice test demonstrate that the pCR rate is not different between the two agents...
Yeah, the GeparOLA study we present here is the long term data and we have already published the pathological complete response data in 2020 in Annals of Oncology, which demonstrated that exchanging carboplatin with olaparib in patients who have HRD, so defined as either BRCA mutation or having a HRD-high tumor by the MyChoice test demonstrate that the pCR rate is not different between the two agents. So basically, olaparib can be used instead of carboplatinum, looking at the pCR rate. But we also want to know how are the long-term outcome data? And here we present the long-term outcome data from the GeparOLA study and the overall cohort where we have, of course, mutant versus wild-type patients demonstrated that in the long run, carboplatinum is better than olaparib. But when we look at the BRCA carriers, there is no difference. The only difference we see is in the wild-type cohort, which still have HRD-high tumors, but they don’t have a mutation in the tumor and here we see the difference between carboplatinum with olaparib.
Read more...
